Author Correction: EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.

Autor: Fillmore CM; Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, 02115, USA.; Department of Genetics, Harvard Medical School, Boston, Massachusetts, 02115, USA.; Harvard Stem Cell Institute, Cambridge, Massachusetts, 02138, USA., Xu C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, USA.; Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, USA., Desai PT; Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, 02115, USA., Berry JM; Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, 02115, USA., Rowbotham SP; Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, 02115, USA.; Department of Genetics, Harvard Medical School, Boston, Massachusetts, 02115, USA.; Harvard Stem Cell Institute, Cambridge, Massachusetts, 02138, USA., Lin YJ; Department of Genetics, Harvard Medical School, Boston, Massachusetts, 02115, USA., Zhang H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, USA.; Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, USA., Marquez VE; Chemical Biology Laboratory, National Cancer Institute, National Institutes of Health, Frederick, Maryland, 21702, USA., Hammerman PS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, USA., Wong KK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, USA.; Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, USA., Kim CF; Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, 02115, USA. carla.kim@childrens.harvard.edu.; Department of Genetics, Harvard Medical School, Boston, Massachusetts, 02115, USA. carla.kim@childrens.harvard.edu.; Harvard Stem Cell Institute, Cambridge, Massachusetts, 02138, USA. carla.kim@childrens.harvard.edu.
Jazyk: angličtina
Zdroj: Nature [Nature] 2018 Nov; Vol. 563 (7732), pp. E27.
DOI: 10.1038/s41586-018-0580-6
Abstrakt: We wish to correct two mutations in Supplementary Table 4 of this Letter. The NCI-H460 cell line was annotated as being mutant for TP53. NCI-H460 has been verified to be TP53 wild type by several sources 1 . The NCI-H2009 cell line was annotated as being mutant for PIK3CA. As annotated by COSMIC (ref. 24 of the original Letter) and CCLE (ref. 25 of the original Letter), the NCI-H2009 cell line has a mutation in PIK3C3, rather than PIK3CA. The cell line is wild type for PIK3CA. The Supplementary Information of this Amendment contains the corrected Supplementary Table 4. These errors do not affect our conclusions. The original Letter has not been corrected.
Databáze: MEDLINE
Externí odkaz: